Background and aims: Sotagliflozin (SOTA) reduces the risk of cardiovascular (CV) death and heart failure events in adults at high CV risk
In these high-risk populations, Semaglutide reduced the risk of heart failure events and cardiovascular death, underscoring its potential in managing complex cardiometabolic conditions This protective effect is attributed to several mechanisms that promote heart health, including: Decreased inflammation Enhanced endothelial function Lowered blood pressure Decrease body weight Tirzepatide has a similar mechanism of action with added benefits due to its dual target on two receptors
This is likely due to the peptides effects on the nervous system and circulation
And, as critics have pointed out over the years, by elevating just one, two, or at most, three researchers, the Nobels distort the history of science by personalizing discoveries that are truly made by groups of individuals. That reality hangs heavy especially over a decision about GLP-1 and other gut-hormone based drugs, given how much additional science had to be done to convert the hormones to effective, and then even more effective, drugs
